Last reviewed · How we verify
NCT03866551
Reprieve ADHF EFS IDE
NA trial testing Reprieve Cardiovascular System in Congestive Heart Failure in 40 participants. Status unknown.
1 December 2019
Quick facts
| Lead sponsor | CardioRenal Systems, Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 May 2019 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 February 2020 |
Drugs / interventions tested
- Reprieve Cardiovascular System
Conditions studied
- Congestive Heart Failure — all drugs for Congestive Heart Failure →
Sponsor
CardioRenal Systems, Inc.
Who can join
18 and older, any sex, with Congestive Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, single arm, early feasibility study (EFS) designed to evaluate the safety and device performance of The RenalGuard System in the management of patients admitted with signs and symptoms of congestive heart failure who require diuresis for the treatment of volume overload.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03866551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Reprieve Cardiovascular System
Trials testing the same drug.
- NCT05015764 — Reprieve Cardiovascular System for the Treatment of Subjects With Acute Decompensated Heart Failure Mechanistic Study · NA · completed
- NCT03897842 — TARGET: A Study to Evaluate the Treatment of Patients With Acute Decompensated Heart Failure (ADHF) Using an Automated F · NA · unknown
Other recruiting trials for Congestive Heart Failure
Currently open trials in the same condition.
- NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
- NCT06526884 — Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC) · NA · active not recruiting
- NCT06495892 — PVP-Guided Decongestive Therapy in HF 2 · Phase 4 · recruiting
- NCT06374277 — Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence · NA · recruiting
- NCT05971225 — Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe) · NA · recruiting
Other CardioRenal Systems, Inc. trials
Trials by the same sponsor.
- NCT07123935 — Safety & Efficacy of RenalGuard® Therapy in the Prevention of Cardiac Surgery Associated Acute Kidney Injury · NA · not yet recruiting
- NCT06811805 — Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI · NA · active not recruiting
- NCT03897842 — TARGET: A Study to Evaluate the Treatment of Patients With Acute Decompensated Heart Failure (ADHF) Using an Automated F · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03866551 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CardioRenal Systems, Inc.
- Last refreshed: 7 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03866551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing